about
Neurobiology of posttraumatic stress disorder.An epigenetic clock for gestational age at birth based on blood methylation data.MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION.Carbamazepine clearance and seizure stability during pregnancy.A serotonin transporter gene polymorphism predicts peripartum depressive symptoms in an at-risk psychiatric cohortThe link between childhood trauma and depression: insights from HPA axis studies in humans.Validity of depression rating scales during pregnancy and the postpartum period: impact of trimester and parityA psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.Temperament and behavior in toddlers of mothers with bipolar disorder: a preliminary investigation of a population at high familial risk for psychopathology.Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk.Maternal expectations of postpartum social support: validation of the Postpartum Social Support Questionnaire during pregnancy.Childhood trauma associated with smaller hippocampal volume in women with major depression.Neonatal DNA methylation patterns associate with gestational age.The fetus and maternal depression: implications for antenatal treatment guidelines.Psychiatric disorders in pregnancy.Test-retest reliability of retrospective self-reported maternal exposure to childhood abuse and neglect.Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentationObsessive-compulsive disorder in pregnancy and the postpartum period: course of illness and obstetrical outcome.Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities.Postpartum depression in women with epilepsy: influence of antiepileptic drugs in a prospective study.The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.Maternal depression and infant cortisol: influences of timing, comorbidity and treatmentPhysiological regulation in infants of women with a mood disorder: examining associations with maternal symptoms and stress.The impact of education, country, race and ethnicity on the self-report of postpartum depression using the Edinburgh Postnatal Depression Scale.Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.Prospective Longitudinal Study of Predictors of Postpartum-Onset Depression in Women With a History of Major Depressive Disorder.Maternal depression in association with fathers' involvement with their infants: spillover or compensation/buffering?Prenatal Psychostimulant and Antidepressant Exposure and Risk of Hypertensive Disorders of Pregnancy.The correlation between Toxoplasma gondii infection and prenatal depression in pregnant women.Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis.Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression.The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis.Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes.Venlafaxine in human breast milk and nursing infant plasma: determination of exposure.Comparison of women with confirmed versus presumably misdiagnosed bipolar disorder.WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?Lamotrigine in bipolar disorder: efficacy during pregnancy.Antidepressants in amniotic fluid: another route of fetal exposure.The neural correlates of social anxiety disorder and response to pharmacotherapy.
P50
Q30589116-0363A5E4-A886-404B-B49F-090997D31F2EQ31135584-DAE56E65-0BC7-460D-B50A-825A56776062Q33683865-8CC022EE-26D7-4CDB-B65A-540243210645Q33696210-5070DE4F-0418-446C-AA9F-8086D7AD3C67Q33940182-25C01B3F-0E3C-4772-9648-67B4AE41A662Q34012622-2A0C9619-154D-4998-AD1B-6A57A64E51E3Q34155607-7FCD6264-E0FC-43CF-8073-D4CCDED69606Q34183517-84F6960B-C258-4036-B2F9-DA9497AADECDQ34564611-C9E32C11-F4BA-4E88-80C0-7BE28587A23FQ34719174-25C0281B-BB5A-4ED3-945B-FA0170E742C2Q35265670-E47243C6-943E-481F-8FE0-25B700A7A5BFQ35521745-B2FF7AA8-7204-4AE0-918D-36B3E1A683A9Q35591603-DB19953A-6E62-4835-A8FE-601884D2C284Q35667395-3B19C4DC-2F56-41AC-A5CD-DEC561D700F5Q35869895-A51F6ED2-5453-47BD-86F2-E13B483A7481Q35913477-E28223A1-E1DF-48EC-B1EA-BEE46690658EQ36279088-DF652AB8-664B-47F1-8B78-C0F55DB9CC63Q36467145-C19186DD-D4DC-4D1A-9065-59197298A208Q36470804-942560AB-082F-48C3-8980-01C54C50236AQ36511686-B68AAE48-C4BB-4543-9585-D3986A7805B2Q36660100-63AF5E3D-BE2F-42CF-8DF9-720F6C7B1820Q37024001-51FF1AD5-482E-422E-B671-C7A9CC81B0AAQ37284647-0BF2E758-CF35-452A-913D-D82091155207Q37625754-FD187CAB-88DD-4FB0-8A55-4CC16BBB1205Q37725218-21DABE49-17C6-4455-8C9C-CD2C972EA781Q38596017-68E3D5D4-4EA8-4203-8DC8-DD686521AA9BQ38905633-D5439143-02BE-4316-B7F7-3847FEA1F468Q39026479-75294A44-5D9C-4971-82B1-78644AA97957Q39026852-DAB8C485-9F86-4317-8FC7-69D732AA0D00Q40583636-59BBF59D-B6A0-47B9-8733-413560B53362Q40601001-B8F9CAAF-D4CF-46E8-ABF9-99AD5888FBC7Q42664778-666439A4-AB49-4E3D-A3B6-0E2958F8AADEQ43986856-2EA976D3-3092-444D-84AE-F99F8A297B65Q44258217-102BB34B-16D6-462D-943D-C6AF57B326E2Q45927857-42986827-9851-47E2-AA30-2CB39805801BQ46077118-3611FCF4-EE00-4D03-9EEB-201850036C27Q46085751-EF1992E6-821D-495C-90EA-12A6F0737E39Q46652522-E91A14DC-0E65-4C76-97F1-874B90DA0870Q46877854-F28C8F02-D468-441A-8CFF-74A3F42F38D6Q46981602-34D2DC6F-2962-4BF5-A10E-3B1AB382C69D
P50
description
researcher
@en
wetenschapper
@nl
name
D Jeffrey Newport
@en
D Jeffrey Newport
@nl
type
label
D Jeffrey Newport
@en
D Jeffrey Newport
@nl
prefLabel
D Jeffrey Newport
@en
D Jeffrey Newport
@nl
P108
P106
P108
P31
P496
0000-0003-1695-9710